LACTB and infection: The antimicrobial agents newly introduced into clinical practice, such as the beta-lactam/beta-lactamase inhibitor ceftazidime/avibactam and meropenem/vaborbactam combinations, eravacycline, the aminoglycoside plazomicin, and the siderophore cephalosporin cefiderocol, represent novel promising therapeutic options for infections caused by carbapenemase-producing enterobacteria [12,13].